Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03702361
Other study ID # 307-17-SZMC
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 4, 2018
Est. completion date March 18, 2021

Study information

Verified date March 2021
Source Shaare Zedek Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During the past two years, the investigator has performed succsefully an IIR wherein patients with GD, previously treated with velaglucerase alfa ERT were gradually switched to a 10 minutes (rapid) administration of the same ERT. The success was expressed as safety (no clinically meaningful AEs, no antibodies detected, home therapy), efficacy ("lack of deterioration") and patients' satisfaction. The latter was based not just on specific questionnaires and analog scales, but particularly by the patients' sharing the experience with other patients and consequently repeated requests by many to switch to a rapid administration of their ERT. Therefore, the investigator is hereby proposing to investigate the safety and efficacy of a 10 minutes administration of velaglucerase alfa in a cohort of treatment-naive patients. The current VPRIV label is restricted to a dosage of 60 units/kg body weight every other week (60 units/kg EOW) - this dose will be used throughout the study period. The enzyme will be provided by Shire, which will also provide a research grant for the conduction of the trial.


Description:

Protocol: Study Design: This will be a single-center, open-label trial to assess the safety and efficacy of rapid administration of velaglucerase alfa (VPRIV) to treatment-naive patients with type I Gaucher disease. The first six infusions will be administered in the hospital: the first three infusions within 60, 30 and 20 minutes each, with the beginning of a 10 minutes administration from infusion #4. Following the three uneventful administration of the 10 minutes in the hospital, the bi-weekly ERT will continue as home therapy, as outlined in the protocol. The duration of the study will be 12 months, with an extension pending positive results. Number of Patients: 15. The first ten patients will be adults, and then children will be allowed to enroll in the trial.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date March 18, 2021
Est. primary completion date September 30, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Years to 75 Years
Eligibility Inclusion Criteria: - Males and females, 18 years or older for the first ten adult patients; 6 years or older for the last five patients. - Confirmed enzymatic diagnosis of Gaucher disease with a defined genotype and elevated biomarker LysoGb1, performed at CentoGene using DBS methodology. - Indications for ERT will be guided by fulfilling the MOH criteria. - Female patients of child-bearing potential who agree to use a medically acceptable method of contraception. - Patients who have not received ERT or SRT in the past or Patients who have not received ERT or SRT in the past 12 months and have a negative anti-glucocerebrosidase antibody Exclusion Criteria: - Currently taking another experimental drug for any condition - Presence of neurologic signs and symptoms characteristic of Type 2 or Type 3 Gaucher disease - Pregnant or nursing - Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VPRIV
VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Locations

Country Name City State
Israel Michal Becker- Cohen Jerusalem Please Select...

Sponsors (1)

Lead Sponsor Collaborator
Shaare Zedek Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Zimran A, Revel-Vilk S, Becker-Cohen M, Chicco G, Arbel N, Rolfs A, Szer J. Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease. Am J Hematol. 2018 Sep;93(9):E246-E248. doi: 10.1002/ajh.25205. Epub 2018 Aug 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change from baseline in spleen volume measured by MRI Percent change from baseline 12 months.
Secondary Change from baseline in Hemoglobin Percent change from baseline 12 months
Secondary Change from baseline in platelet count Percent change from baseline 12 months
Secondary Change from baseline in Lyso-GB1 Percent change from baseline 12 months
Secondary Change from baseline in liver volume Percent change from baseline 12 months
Secondary Change from baseline 10% reduction in spleen volume Percent change from baseline 6 months
See also
  Status Clinical Trial Phase
Completed NCT00405210 - Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer Phase 1
Completed NCT01325194 - CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis Phase 2
Completed NCT00803244 - Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma) Phase 3
Completed NCT01214798 - A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking N/A
Completed NCT00552461 - Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Phase 2
Terminated NCT01868243 - Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively Phase 2/Phase 3
Completed NCT01323894 - Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling N/A